Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | TLR2 | O60603 | 3/20 | 0.50 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29812585 | 1.00 | KMT2A (0.53) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL29768865 | 1.00 | KMT2A (0.53) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL24246257 | 1.00 | KMT2A (0.53) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL24246233 | 0.98 | KMT2A (0.52) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL999302 | 0.92 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL2292778 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL1738182 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL2524769 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL30886226 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL12040103 | 0.92 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015381-A | Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023186072-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 江苏先声药业有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-111417410-B | Glucocorticoid receptor agonists and immunoconjugates thereof | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116096413-A | Anti-human VISTA antibodies and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3884962-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3658192-B1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210015938-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3716982-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10772970-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | ABBVIE INC. (US) | 2020-09-15 | — | — | US | disclosed |
| CN-111465399-A | anti-CD 40 antibody drug conjugates | 艾伯维公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-111417410-A | Glucocorticoid receptor agonists and immunoconjugates thereof | 艾伯维公司 | 2020-07-14 | — | — | CN | disclosed |
| EP-3658192-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190167804-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. | 2019-06-06 | — | — | US | disclosed |
| WO-2015095953-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772970-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | NR3C1, NR3C2, MC2R | KMT2A 4167/4885MDM2 1967/4885TLR2 235/4885 |
| US-20190167804-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | KMT2A 4167/4885MDM2 1967/4885TLR2 235/4885 |
| US-20210015938-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | KMT2A 4167/4885MDM2 1967/4885TLR2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.